CHMP2A antibody (AA 1-100) (FITC)

Catalog No. ABIN2559696

The Rabbit Polyclonal anti-CHMP2A antibody has been validated for WB, IF (cc) and IF (p). It is suitable to detect CHMP2A in samples from Rat.

Quick Overview for CHMP2A antibody (AA 1-100) (FITC) (ABIN2559696)

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Reactivity: Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CHMP2A antibody is conjugated to FITC

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details anti-CHMP2A Antibody (FITC)

Binding Specificity: AA 1-100

Cross-Reactivity: Rat

Predicted Reactivity: Human,Mouse,Dog,Sheep

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human CHMP2A

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for CHMP2A

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Alternative Name: CHMP2A

Background:

Synonyms: BC2, BC-2, VPS2, CHMP2, VPS2A, Charged multivesicular body protein 2a, Chromatin-modifying protein 2a, CHMP2a, Putative breast adenocarcinoma marker BC-2, Vacuolar protein sorting-associated protein 2-1, Vps2-1, hVps2-1

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.

Gene ID: 27243

UniProt: O43633

Pathways: SARS-CoV-2 Protein Interactome